TOLERABILITY AND TUMOR RESPONSE OF A NOVEL LOW‐DOSE PALLIATIVE RADIATION THERAPY PROTOCOL IN DOGS WITH TRANSITIONAL CELL CARCINOMA OF THE BLADDER AND URETHRA

Previously reported radiation protocols for transitional cell carcinoma of the canine lower urinary tract have been ineffective or associated with increased side effects. Objectives of this retrospective, cross‐sectional study were to describe safety of and tumor responses for a novel palliative radiation protocol for transitional cell carcinoma in dogs. Included dogs had cytologically or histologically confirmed transitional cell carcinoma of the bladder or urethra, and were treated with 10 once‐daily fractions (Monday–Friday) of 2.7 Gy. Thirteen dogs were sampled, with six treated using radiation as first‐line (induction) therapy and seven treated using radiation as rescue therapy after failing previous chemotherapy. Within 6 weeks of radiation, 7.6% (1/13) dogs had a complete response, 53.8% (7/13) partial response, 38.5% (5/13) stable disease, and none had progressive disease. Three patients presenting with urethral obstruction had spontaneous micturition restored during the treatment protocol. A single patient with unilateral ureteral obstruction was patent at recheck examination. Median survival time from time of initial diagnosis was 179 days. Median survival time from start of radiation was 150 days. Acute radiation side effects occurred in 31% (4/13) patients and were classified as grade 1 or 2. No significant late side radiation side effects were reported. No variables examined were identified as prognostic factors. Findings indicated that the reported radiation protocol was safe in this sample of dogs with bladder and urethral transitional cell carcinoma. Future prospective studies are needed to determine utility of this treatment as a rescue therapy in patients with complete urinary tract obstruction.     

CLINICAL,DIAGNOSTIC, AND PATHOLOGICAL FEATURES OF 2 CASES OF METASTATIC IRIDOPHOROMA IN A VEILED CHAMELEON (CHAMAELEO CALYPTRATUS) AND A RED-BARRED DRAGON (CTENOPHORUS VADNAPPA)

Iridophores are iridescent cutaneous pigment cells found in reptiles, fish, and amphibians. Neoplasms of iridophores are rarely reported, and little is known about their behaviour, metastatic potential, and prognostic indicators. This paper reports details of the clinical course and pathological findings of metastatic iridophoroma in a veiled chameleon (Chamaeleo calyptratus) and red-barred dragon (Ctenophorus vadnappa). The veiled chameleon presented with a subcutaneous mass on the right lateral elbow and was diagnosed as an iridophoroma on fine needle aspiration. It was otherwise clinically normal. Within 35 days of excision, multiple secondary skin masses developed which were often non-pigmented and required microscopic examination to identify them as iridophoroma metastases. There were in total 54 days between the first detection of the primary mass and end stage, extensive cutaneous and visceral metastatic disease, and there had been no detectable primary mass during routine clinical examination 128 days prior to death. The red-barred dragon presented with a white sub-mandibular mass. While undergoing an excisional biopsy the animal expired, post-mortem examination revealed a cutaneous malignant iridophoroma with tumour cell clusters seen in pulmonary arterial vessels, suggesting that surgical handling of iridophoroma could precipitate the release of circulating tumour cell clusters. This is the first iridophoroma described in a red-barred dragon and the second report of a malignant iridophoroma in a veiled chameleon. Timely detection and careful excision of lizard iridophoroma may be an important factor in clinical outcome.     

INTRAVENOUS ALFAXALONE ANAESTHESIA IN LEOPARD GECKOS (EUBLEPHARIS MACULARIUS)

Intravenous alfaxalone, administered at a dose of 5 mg/kg in the jugular vein, was evaluated in 20 leopard geckos (Eublepharis macularius) to ascertain its ability to provide anesthesia. The induction time, time to loss of mandibular tone, interval of deep anesthesia, and full recovery time were 27.5 ± 30.7 seconds (10 to 56 seconds), 1.3 ± 1.4 minutes (11 seconds to 4 minutes), 12.5 ± 2.2 minutes (11.11 to 15.39 minutes), and 18.8 ± 12.1 minutes (10.4 to 52.31 minutes), respectively. A significant reduction in heart rate (74 ± 12.9 beats/minute) was recorded between 2 and 24 minutes after alfaxalone administration. A significant decrease in respiratory rate (26.8 ± 10.1 breaths/minute) was recorded 2 minutes after alfaxalone administration, and respiratory rate remained lower than the basal rate (31.4 ± 3.1 breaths/minute) for 24 minutes but without statistical significance. The intravenous administration of alfaxalone in leopard geckos achieved a rapid onset of anesthesia and a suitable recovery time. Based on this investigation, an afaxalone dose of 5 mg/kg intravenously proved to be suitable for sedation before tracheal intubation. Moreover, the administration route via the jugular vein, was acceptable in leopard geckos; a species in which other venipuncture sites can be challenging or inaccessible.